心脏外科手术中的Levosimendan与Milrinone:一个GRADE评估的系统审查和元分析
Ahmed Emara1, Mohamed Ellebedy2, Heba Aboeldahab3,4
1Faculty of Medicine, Al-Azhar University, Cairo, Egypt. emara9055@gmail.com.
European journal of clinical pharmacology
|January 17, 2026
概括
在心脏手术患者中,Levosimendan和Milrinone的疗效和安全性相似. 宽的置信区间表明潜在的临床差异,需要个性化治疗方法. 建议进行进一步的研究.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 关键护理医学 关键护理医学
背景情况:
- 莱沃西门丹和米利诺经常用于心脏手术患者的内药物.
- 关于这两种药物在这个患者群体中的安全性和有效性,目前的比较数据有限.
研究的目的:
- 进行系统性审查和元分析,比较levosimendan与Milrinone在成人和儿童心脏手术患者的临床疗效和安全性.
主要方法:
- 一个系统的审查和元分析,遵循PRISMA指南.
- 在PubMed,Scopus,Web of Science和Cochrane中央数据库中搜索到2024年11月30日.
- 使用几率比率 (OR) 的二分法数据和使用平均差异 (MD) 的连续数据与使用R统计软件的95%置信区间 (CI).
主要成果:
- 包括17项研究 (15项RCT,2项观察性) 涉及890名患者.
- 对于疗效结果 (心脏指数,MAP,mPAP) 或安全结果 (全因死亡率,AKI,心律失常) 之间没有观察到levosimendan和Milrinone的显著差异.
- 所有P值都超过0.05,表明没有统计学上显著的差异.
结论:
- 在心脏手术患者中,Levosimendan和Milrinone的疗效和安全性表现相似.
- 宽的置信区间表明可能存在临床相关的效应,因此需要谨慎解释.
- 建议基于表型和机构协议的个性化患者管理,需要进一步进行高质量的试验.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
942
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
942
01:26Heart Failure Drugs: Inotropic Agents
1.3K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.3K
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
4.0K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
4.0K
01:26Mitral Stenosis III: Medical Management
247
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
247
01:30Heart Failure V: Medical Management
223
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
223
01:25Mitral Regurgitation III: Medical Management
284
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
284